Summit Therapeutics's total assets for Q2 2024 were $341.86M, an increase of 93.38% from the previous quarter. SMMT total liabilities were $146.78M for the fiscal quarter, a 10.72% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.